<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a 36-year-old male with myeloid/natural killer (NK)-cell precursor <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> with a complex aberrant karyotype, who was treated according to an <z:hpo ids='HP_0011009'>acute</z:hpo>-<z:mpath ids='MPATH_342'>myeloid-leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) treatment protocol (idarubicine, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and <z:chebi fb="0" ids="4911">etoposide</z:chebi>) followed by high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> consolidation and achieved complete remission </plain></SENT>
<SENT sid="1" pm="."><plain>He underwent allogeneic matched unrelated donor (MUD) peripheral blood stem-cell transplantation (PBSCT) and remained in remission throughout his remaining life </plain></SENT>
<SENT sid="2" pm="."><plain>Seven months posttransplantation, a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with (20q-) of donor origin was diagnosed causing severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and finally leading to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>This patient represents one of the few cases published achieving remission for a significant period of time after being diagnosed with myeloid/NK-cell precursor <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, a very rare malignant disease </plain></SENT>
<SENT sid="4" pm="."><plain>We conclude, despite the fatal outcome due to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, that allogeneic PBSCT is a therapeutic option for patients with this entity </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the development of a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> of donor origin is extremely rare and only very few cases are published worldwide </plain></SENT>
</text></document>